BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?

Key Takeaways BEAM and NTLA are compared as gene editing biotechs with pipelines at different development stages.BEAM advances multiple SCD programs and updates its BEAM-101 and BEAM-301 studies across phases.NTLA pushes late-stage in vivo candidates while a clinical hold on nex-z raises safety concerns.Beam Therapeutics (BEAM) and Intellia Therapeutics (NTLA) are clinical-stage companies developing investigational gene therapies. While BEAM’s pipeline candidates are still in early-stage development, NTLA i ...